Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_assertion description "[The incidence of TET2, ASXL1, CBL, IDH or IKZF1 mutations in these disorders ranges from 0 to 17%; these latter mutations are more common in chronic (TET2, ASXL1, CBL) or juvenile (CBL) myelomonocytic leukemias, mastocytosis (TET2), myelodysplastic syndromes (TET2, ASXL1) and secondary acute myeloid leukemia, including blast-phase MPN (IDH, ASXL1, IKZF1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_assertion evidence source_evidence_literature NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_assertion SIO_000772 20428194 NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_assertion wasDerivedFrom befree-20150227 NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_assertion wasGeneratedBy ECO_0000203 NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.
- befree-20150227 importedOn "2015-02-27" NP286393.RAk7KmTH4DL3NH5pkD6xXbJh570xokVYSjFNuegHVY_Lk130_provenance.